Dulcolax®
-
Dokumente
-
Transparency
Transparency is an essential cornerstone of trust in the healthcare industry
-
Geog van Husen
Cardiovascular
Presented by Dr. Georg van Husen, Therapy Head Cardiovascular at Boehringer Ingelheim
-
Research & Development
-
Vision
The Boehringer Ingelheim group of companies' objectives and beliefs can be summed up in a single phrase: Value through Innovation, the central concept of our corporate vision.
-
PRESS RELEASE
Human Pharma business grows by seven percent, Animal Health gains over eight percent, total sales reach EUR 897.5 million
-
PRESS RELEASE
Operating growth outpaces the market in all businesses. Well-filled research pipeline in oncology, fibrotic diseases, immunology and metabolic diseases.
-
-
Mirela Ciocirlan_card
Who we are
On the occasion of International Women's Day, Mirela Ciocirlan, Head of Human Pharma Countries RCV at Boehringer Ingelheim, reveals her personal experiences and insights on the way to senior management.
-
BI Office Hours
Who we are
Boehringer Ingelheim invites innovative biomedical start-ups and entrepreneurs to join the next BI Office Hours at the Vienna BioCenter. A great opportunity to benefit from BI’s science and business know-how.
-
Header A Unique Bond
A Unique Bond
A Unique Bond between humans and animals. Get to know patients and their pets, which helped them through tough times.
-
A Unique Bond Caroline COPD
-
A Unique Bond Eric Diabetes Card
-
A Unique Bond Anna Systemic Sclerosis Card
-
A Unique Bond Phil Schlaganfall Card
-
A Unique Bond Helga Brustkrebs Card
-
-
-
Who we are
We are proud to be honored with the international Prix Galien 2018 as an innovation and research leader in the field of Diabetes therapy.